The **Connect® Myeloid Disease Registry** is a study that aims to learn more about how myeloid diseases, like certain blood cancers, are treated. It will look at how treatments affect patients' health outcomes and what might predict how well these treatments work. **Myeloid diseases** can involve the blood and bone marrow, like **Acute Myeloid Leukemia (AML)**, **Myelodysplastic Syndromes (MDS)**, and **Myelofibrosis (MF)**. The registry will collect information about patient characteristics, treatments, and outcomes.

**Eligibility Criteria:** - Participants need to be able to give consent and understand English or Spanish. - AML patients must be at least 55 years old, while others need to be 18 or older. - Patients should be newly diagnosed or have started treatment recently.

**Key Points to Consider:**

• The study collects data regularly but does not change your treatment plan.
• No new treatments are provided; it only observes standard care.
• Participants should not be in another trial with unknown treatments.